The WHO‑ISoP Pharmacovigilance Curriculum: 2026 Update

dc.AffiliationOctober University for modern sciences and Arts MSA
dc.contributor.authorJürgen Beckmann
dc.contributor.authorMarco Tuccori
dc.contributor.authorPriya Bahri
dc.contributor.authorFrancesco Salvo
dc.contributor.authorMónica Tarapués
dc.contributor.authorManal M. Younus
dc.contributor.authorHussain Al Ramimmy
dc.contributor.authorMayada Alkhakany
dc.contributor.authorThamir Alshammari
dc.contributor.authorBeate Aurich
dc.contributor.authorNicole Baker
dc.contributor.authorMadhava Balakrishnan
dc.contributor.authorGhita Benabdallah
dc.contributor.authorPernette Bourdillon Esteve
dc.contributor.authorIan Boyd
dc.contributor.authorSiva Kumar Buddha
dc.contributor.authorGianmario Candore
dc.contributor.authorEmiliano Cappello
dc.contributor.authorAngela Caro‑Rojas
dc.contributor.authorRebecca Chandler
dc.contributor.authorJerin Jose Cherian
dc.contributor.authorKaren Cohen
dc.contributor.authorSalvatore Crisafulli
dc.contributor.authorShelley Deeks
dc.contributor.authorJean‑Christophe Delumeau
dc.contributor.authorMoin Don
dc.contributor.authorJoan Dsouza
dc.contributor.authorErnest D. Dzidzornu
dc.contributor.authorBrian D. Edwards
dc.contributor.authorI. Ralph Edwards
dc.contributor.authorJefman Efendi Marzuki HY
dc.contributor.authorAlbert Figueras
dc.contributor.authorMohammed I. Fouda
dc.contributor.authorAyako Fukushima
dc.contributor.authorGiovanni Furlan
dc.contributor.authorGeorgy Genov
dc.contributor.authorGloria Giraldo
dc.contributor.authorMichael Gold
dc.contributor.authorTarek Hammad
dc.contributor.authorKenneth Hartigan‑Go
dc.contributor.authorMaria Teresa Herdeiro
dc.contributor.authorRichard Hill
dc.contributor.authorNoha Iessa
dc.contributor.authorKatarina Ilic
dc.contributor.authorSujeet Jain
dc.contributor.authorEunMi Kim
dc.contributor.authorLarissa Kopp
dc.contributor.authorVeronique Kugener
dc.contributor.authorSmaragda Lamprianou
dc.contributor.authorNavinisha Lee
dc.contributor.authorMarie Lindquist
dc.contributor.authorMichaela Lucas
dc.contributor.authorViola Macolic Sarinic
dc.contributor.authorIshak Mansi
dc.contributor.authorUshma C. Mehta
dc.contributor.authorJohanna C. Meyer
dc.contributor.authorJoseph Mitchell
dc.contributor.authorMaryam Naeem
dc.contributor.authorComfort Ogar
dc.contributor.authorLadi Owolabi
dc.contributor.authorJayesh Pandit
dc.contributor.authorLembit Rägo
dc.contributor.authorEmanuel Raschi
dc.contributor.authorHadir Rostom
dc.contributor.authorMulugeta Russom
dc.contributor.authorGeorge T. Sabblah
dc.contributor.authorMaribel Salas
dc.contributor.authorSouad Skalli
dc.contributor.authorFumihito Takanashi
dc.contributor.authorMichael Tatley
dc.contributor.authorGianluca Trifro
dc.contributor.authorClaudia Vaca
dc.contributor.authorFlorence van Hunsel
dc.contributor.authorEugène van Puijenbroek
dc.contributor.authorJessica Liliana Vargas‑Neri
dc.contributor.authorRyan J. Walker
dc.contributor.authorXinyu Weng
dc.contributor.authorIan C. K. Wong
dc.contributor.authorQun‑Ying Yue
dc.contributor.authorLi Zhang
dc.contributor.authorOmar Aimer
dc.contributor.authorShanthi N. Pal
dc.date.accessioned2026-10-08T21:21:07Z
dc.date.issued2026-09-20
dc.descriptionSJR 2025 1.452 Q1 H-Index 151 Subject Area and Category: Medicine Pharmacology (medical) Pharmacology, Toxicology and Pharmaceutics Pharmacology Toxicology
dc.description.abstractThis article presents a pharmacovigilance (PV) curriculum which was jointly developed by the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP). It is an expanded update of a PV curriculum which WHO and ISoP developed in 2014 and responds to major scientific, technological, regulatory, social and public health developments that have reshaped PV over the last 12 years. Topics such as advanced therapies, global health emergencies, antimicrobial resistance, digital health, artificial intelligence, real-world evidence, medical device safety, the environmental impact of medicines, risk communication and patient engagement are addressed. The curriculum was developed through an international collaboration involving 82 contributors from different regions and professional backgrounds. The original three-level hierarchical structure was retained, with each chapter divided into four sections and each section into five or six subsections. The number of chapters increased from 15 to 26, the number of practical tasks from 40 to 125 and the number of references from 260 to 469. Practical tasks and references are provided as Electronic Supplementary Materials. The curriculum provides a comprehensive and structured inventory of contemporary PV and thus represents a reference that lecturers and institutions can use to develop context-specific training programmes. Its structure provides conceptual clarity while allowing adaptation to different settings, learners’ roles and prior knowledge, local priorities, available time and resources. It is not intended to prescribe a single standardised course. Instead, it supports the development of introductory, advanced, comprehensive or topic-specific PV education programmes. The update reflects a shared commitment of the WHO and the ISoP to strengthening PV education and capacity across regulatory, academic, healthcare, public health and industrial settings in accordance with the recommendation of the 2026 World Health Assembly to strengthen PV.
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=21237&tip=sid&clean=0
dc.identifier.citationBeckmann, J., Tuccori, M., Bahri, P., Salvo, F., Tarapués, M., Younus, M. M., Al Ramimmy, H., Alkhakany, M., Alshammari, T., Aurich, B., Baker, N., Balakrishnan, M., Benabdallah, G., Bourdillon Esteve, P., Boyd, I., Buddha, S. K., Candore, G., Cappello, E., Caro-Rojas, A., … Pal, S. N. (2026). The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update. Drug Safety. https://doi.org/10.1007/s40264-026-01717-y
dc.identifier.doihttps://doi.org/10.1007/s40264-026-01717-y
dc.identifier.otherhttps://doi.org/10.1007/s40264-026-01717-y
dc.identifier.urihttps://repository.msa.edu.eg/handle/123456789/6872
dc.language.isoen_US
dc.publisherSpringer Nature
dc.relation.ispartofseriesDrug Safety; 2026
dc.subjectHepatitis B
dc.subjectPharmacodynamics
dc.subjectStandards
dc.subjectMedical Education
dc.subjectDrug Safety and Pharmacovigilance
dc.subjectCurriculum Studies
dc.titleThe WHO‑ISoP Pharmacovigilance Curriculum: 2026 Update
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s40264-026-01717-y.pdf
Size:
701.56 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: